Sinopharm Holdings (01099.HK): Main business maintains growth trend, transformation and innovation continue to advance

Revenue for the first quarter of 2024 was in line with our expectations, and net profit was slightly lower than our expectations. The company announced the results for the first quarter of 2024: revenue of RMB 147.27 billion, an increase of 1.2% over the previous year, and net profit attributable to the parent company RMB

中金公司Apr 30 19:11

Sinopharm Holdings (01099) plans to uniformly register and issue 30 billion yuan of non-financial corporate debt financing instruments in China

Sinopharm Holdings (01099) announced that in order to meet the company's actual needs for supplementary operation and provision of capital, it guarantees direct financing channels...

Zhitong FinanceApr 29 08:10

Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK

Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK

Dow JonesApr 29 08:07

Sinopharm Holdings (01099) announced first-quarter results, net profit of about 1.42 billion yuan, a year-on-year decrease of 10.7%

Sinopharm Holdings (01099) announced its results for the first quarter of 2024, with total revenue of about 147.266 billion yuan,...

Zhitong FinanceApr 29 08:06

國藥控股：公告 截至 2024 年 3 月 31 日止三個月之季度財務資料

Futu NewsApr 29 08:00 · Announcements

國藥控股：年度報告2023

Futu NewsApr 26 16:30 · Announcements